on this page
Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with ponatinib under the National Health Act 1953, section 85 for patients with chronic myeloid leukaemia (CML).
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing ponatinib.
Authority Applications
Applying for initial treatment
Applications for initial authority approval to prescribe PBS-subsidised ponatinib to treat CML can be made either in:
- real time using the Online PBS Authorities system
- writing and upload through Health Professional Online Services (HPOS)
- writing and post to PBS Complex Drugs Programs.
All written applications must include the completed:
- authority prescription form or forms
- Chronic myeloid leukaemia - ponatinib - initial authority application form
- relevant attachments.
Applying for continuing treatment
Applications for first continuing authority approval to prescribe PBS-subsidised ponatinib to treat CML can be made either in:
- real time using the Online PBS Authorities system
- writing and either upload through HPOS
- writing and post to PBS Complex Drugs Programs.
All written applications must include the completed:
- authority prescription form or forms
- Chronic myeloid leukaemia - ponatinib - continuing authority application form
- relevant attachments.
After we approve the first continuing application for ponatinib treatment, subsequent continuing applications can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
More information
Call the PBS Complex Drugs Programs enquiry line for more information.